High-Dose Vitamin D3 Study in HIV+ Smokers Terminated Prematurely

Individuals with HIV/AIDS and smokers often experience vitamin D deficiency and compromised immune function, increasing their susceptibility to infections. Previous in vitro research suggested that vitamin D supplementation could enhance phagocytosis in HIV+ macrophages, indicating a potential to improve overall immune response. However, the in vivo impact of a single high dose of Vitamin D3 on innate immune function in these vulnerable populations, particularly concerning alveolar macrophage function and oxidative stress, remained underexplored.

The study was TERMINATED prematurely on October 15, 2018, before its scheduled completion, meaning no primary or secondary outcome data were collected or reported. The researchers had aimed to evaluate the impact of a single high dose of Vitamin D3 (450,000 IU) on alveolar macrophage function, LL-37 levels, and oxidative stress in HIV+ smokers and HIV- smokers. The primary goal was to improve innate immune host response to infection in these high-risk patient groups. Due to the premature termination of the study, no conclusions could be drawn regarding the efficacy or safety of high-dose Vitamin D3 in the target populations. Therefore, no quantitative comparisons between treatment and control groups could be made, and no specific p-values or fold-changes were generated.